SABCS: HR+/HER2– Spotlight

Discover groundbreaking results from the lidERA study, showcasing giredestrant's potential to redefine treatment for early breast cancer patients.

Giredestrant combined with everolimus significantly improves progression-free survival in advanced ER+, HER2-negative breast cancer after CDK4/6 inhibitors.

Gedatolisib combined with fulvestrant shows significant progression-free survival benefits in advanced breast cancer, regardless of prior treatment duration.

Long-term PALLAS study results reveal no survival advantage for palbociclib plus endocrine therapy over endocrine therapy alone in breast cancer patients.

Elacestrant shows promising results in combination therapies for ER-positive, HER2-negative metastatic breast cancer, enhancing progression-free survival and maintaining safety.

Alpelisib plus fulvestrant significantly improves progression-free survival in advanced breast cancer patients previously treated with CDK4/6 inhibitors.

Circulating tumor DNA analysis offers a minimally invasive method for detecting key genetic alterations in hormone receptor-positive breast cancer patients.

New trial data reveals that combining preoperative radiation with pembrolizumab enhances immune response in high-risk, early-stage breast cancer patients.

Abemaciclib shows promise as a monotherapy for HR-positive, HER2-negative breast cancer after CDK4/6 inhibitor failure, benefiting 33% of patients.

Giredestrant shows significant improvement in invasive disease-free survival for early breast cancer patients, outperforming standard endocrine therapy in a pivotal trial.